Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep-Oct;37(5):1784-1793.
doi: 10.1111/jvim.16804. Epub 2023 Jul 4.

Thirty-two cats with effusive or non-effusive feline infectious peritonitis treated with a combination of remdesivir and GS-441524

Jodie Green  1 , Harriet Syme  1 , Sarah Tayler  1
Affiliations

Thirty-two cats with effusive or non-effusive feline infectious peritonitis treated with a combination of remdesivir and GS-441524

Jodie Green et al. J Vet Intern Med. 2023 Sep-Oct.

Abstract

Background: GS-441524 has been successfully used to treat feline infectious peritonitis (FIP) in cats. However, the use of its prodrug, remdesivir, in combination with a PO GS-441524 containing product for the treatment of FIP has not yet been described.

Objectives: Describe treatment protocols, response to treatment and outcomes in cats with FIP treated with a combination of PO GS-441524 and injectable remdesivir.

Animals: Thirty-two client-owned cats diagnosed with effusive or non-effusive FIP including those with ocular and neurological involvement.

Methods: Cats diagnosed with FIP at a single university hospital between August 2021 and July 2022 were included. Variables were recorded from time of diagnosis, and subsequent follow-up information was obtained from the records of referring veterinarians. All surviving cats were observed for the entire 12-week treatment period.

Results: Cats received treatment with different combinations of IV remdesivir, SC remdesivir, and PO GS-441524 at a median (range) dosage of 15 (10-20) mg/kg. Clinical response to treatment was observed in 28 of 32 cats (87.5%) in a median (range) of 2 (1-5) days. Twenty-six of 32 cats (81.3%) were alive and in clinical and biochemical remission at the end of the 12-week treatment period. Six of 32 cats (18.8%) died or were euthanized during treatment with 4 of the 6 cats (66%) dying within 3 days of starting treatment.

Conclusions: We describe the effective use of injectable remdesivir and PO GS-441524 for the treatment of FIP in cats. Success occurred using different treatment protocols and with different presentations of FIP including cats with ocular and neurological involvement.

Keywords: FIP; coronavirus; feline; microbiology; neurology; viral.

PubMed Disclaimer

Conflict of interest statement

United Kingdom based Specials Company BOVA contributed financially to the treatment of 1 cat in this study.

Figures

FIGURE 1
FIGURE 1
Diagram reflecting the different presentations of feline infectious peritonitis for the 32 cats included in this study. *One cat was excluded due to the owner obtaining non‐licensed GS‐441524 4 weeks into the treatment period.
FIGURE 2
FIGURE 2
Diagram depicting the different treatment courses with remdesivir and GS‐441524 for 32 cats diagnosed with effusive and non‐effusive feline infectious peritonitis.
FIGURE 3
FIGURE 3
Box and whisker plot depicting albumin: globulin ratios of 25 cats with feline infectious peritonitis at 4, 8, and 12 weeks into treatment with remdesivir and/or GS441524.
See this image and copyright information in PMC

References

    1. Vennema H, Poland A, Foley J, Pedersen NC. Feline infectious peritonitis viruses arise by mutation from endemic feline enteric coronaviruses. Virology. 1998;243:150‐157. - PMC - PubMed
    1. Murphy BG, Perron M, Murakami E, et al. The nucleoside analogue GS‐441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies. Vet Microbiol. 2018;219:226‐233. - PMC - PubMed
    1. de Clercq E. Antivirals and antiviral strategies. Nat Rev Microbiol. 2004;2:704‐720. - PMC - PubMed
    1. Sheahan T, Sims A, Graham R, et al. Broad‐spectrum antiviral GS‐5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9:396. - PMC - PubMed
    1. Eastman RT, Roth JS, Brimacombe KR. Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID‐19. ACS Cent Sci. 2020;6:672‐683. - PMC - PubMed